CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
MWN-AI** Summary
CytoMed Therapeutics Limited (NASDAQ: GDTC), a clinical-stage biopharmaceutical company based in Singapore, announced the completion of its acquisition of allogeneic gamma delta T cell technology, known as “TCB-002,” from UK-based TC BioPharm Limited. This acquisition aligns with CytoMed’s mission to develop affordable cell-based immunotherapies targeting various cancers, including blood and solid tumors. The technology has previously completed a Phase I clinical trial in Europe, receiving orphan drug designation from the U.S. FDA for treating Acute Myeloid Leukemia.
The acquisition comes at a strategic time, as CytoMed is currently in discussions with partners to adapt TCB-002 for cancer treatment in China and India. The goal is to establish a manufacturing process using cytokine production in China, which can lower costs and facilitate easier scaling due to the country’s stringent biological material regulations. The shift to this non-cell-based, donor-derived approach offers advantages over traditional autologous therapies by improving treatment speed, accessibility, and cost-effectiveness.
Additionally, this initiative coincides with new regulatory changes in China, such as State Council Decree No. 818, which outlines a clear pathway for clinical applications of cellular therapies while integrating them into medical service pricing systems. CytoMed’s Chairman, Peter Choo, emphasized the potential for the company to introduce its patented gamma delta T cell platform in the Chinese market successfully.
While the financial implications of this acquisition are not expected to be immediate, CytoMed continues to pursue further innovations and partnerships to enhance its offerings and is currently conducting an IND Phase I clinical trial in Singapore. The company seeks to leverage its proprietary technologies to navigate the evolving biopharmaceutical landscape in Asia.
MWN-AI** Analysis
The recent acquisition of T Cell technology by CytoMed Therapeutics (NASDAQ: GDTC) marks a strategic turning point in the company’s trajectory within the burgeoning biopharmaceutical landscape, particularly in the cancer treatment domain in China and India. With this acquisition of the allogeneic gamma delta T cell technology (TCB-002), CytoMed is positioning itself to capitalize on advancements in immunotherapies that are both effective and cost-efficient.
As the Chinese market opens its doors wider to cellular therapies—evidenced by recent regulatory updates that streamline the pathway for clinical application—CytoMed's decision to pivot towards a non-cell-based methodology for manufacturing these therapies is astute. Leveraging local resources reduces costs significantly, which is crucial in markets characterized by high patient volumes and price sensitivity.
Investors should note that while the current financial impact of the acquisition may be negligible, the long-term implications could be substantial. CytoMed is not just acquiring technology; it is potentially establishing a foothold in one of the largest and fastest-growing healthcare markets worldwide. The ability to deliver off-the-shelf therapies could accelerate market entry and capture share in a landscape dominated by patient-specific treatments.
However, it is essential to consider risks associated with execution and market penetration. As the company navigates partnerships to enhance TCB-002's applications, maintaining focus on its core competencies and adhering to regulatory standards will be paramount.
In conclusion, while CytoMed’s current stock may not reflect immediate value, the strategic acquisition and operational shift signal a promising outlook for future growth. Investors seeking exposure to innovative cancer therapies in emerging markets should keep a close eye on CytoMed as it works to transform cancer treatment paradigms in Asia.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology (termed “TCB-002”) of TC BioPharm Limited (“TCBL”), a subsidiary of TC BioPharm (Holdings) PLC (OTC:TCBPY). This follows CytoMed’s announcement on October 14, 2025 regarding its proposed acquisition of potentially synergistic assets from TCBL.
TCB-002 will complement CytoMed’s strategy to establish a next-generation non-viral allogeneic gamma delta T cell immunotherapy platform to treat cancer and autoimmune diseases. The acquired technology for TCB-002 has previously completed a Phase I clinical trial in Europe and was granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Acute Myeloid Leukemia.
CytoMed is currently in advanced collaborative discussions with prospective partners to further enhance and repurpose this technology for cancer treatment applications in China and India. This prospective collaboration seeks, amongst other things, to jointly develop and commercialize a new method of manufacturing donor-derived unmodified allogeneic gamma delta T cells. This method does not require the use of living cell. Instead, it uses cytokine that can be manufactured in China at lower cost. Because China currently has strict rules governing the import and export of biological materials, this non-cell-based approach can be more easily used and scaled within China. Allogeneic therapies (cells derived from non-patient donors) have the advantage of treatment speed, accessibility and cost-effectiveness compared to autologous therapies (cells derived from the patient).
This new initiative to establish a China beachhead replaces the two earlier agreements with Chinese parties announced on December 5, 2023 and August 15, 2023 and comes on the heel of recently announced new regulations adopted at the 68 th Executive Meeting of the State Council in September 2025 to liberalize the clinical use of cellular products.
“State Council Decree No. 818 released on October 10, 2025 establishes a definitive regulatory pathway from clinical research to reimbursable clinical application for cell therapies in China. The key distinction is that these therapies are to be regulated as biotechnological medical procedures under a ‘clinical study to clinical application’ pathway within the health system, rather than following the traditional drug registration process. This approach creates a mechanism for approved therapies to be incorporated into medical service pricing systems, providing a tailored and timely opportunity for CytoMed to introduce its patented, off-the-shelf allogeneic gamma delta T cell platform to China.” stated CytoMed’s Chairman Peter Choo.
CytoMed’s proprietary gamma delta T cell technology and the associated chimeric antigen receptor gamma delta T cell (CAR-?? T cell) technology have been granted a patent by the China National Intellectual Property Administration (CNIPA). The Company is currently conducting an Investigational New Drug (IND) Phase I first-in-human clinical trial in Singapore at the National University Hospital Singapore. It is also pursuing INDs in Malaysia which is rapidly becoming an international medical tourism hub of choice due to its affordable medical facilities.
The completion of this acquisition and related arrangements is not expected to have an immediate material financial impact on the Company.
CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG , on LinkedIn , and Facebook .
Forward Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&D programs; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
Contact:
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention : Evelyn Tan, Chief Corporate Officer
FAQ**
How does the acquisition of TCB-002 by CytoMed Therapeutics Limited (GDTC) position the company within the competitive landscape of cell-based immunotherapy, especially in the context of regulatory changes in China?
Can you elaborate on the strategic advantages of CytoMed Therapeutics Limited (GDTC) utilizing a non-cell-based manufacturing approach for TCB-00particularly in the context of reducing costs within the Chinese market?
What potential impacts do you foresee on the financial performance of CytoMed Therapeutics Limited (GDTC) as it expands its operations and initiatives in China, considering the recent regulatory advancements in the country?
How will the partnership discussions with prospective collaborators in China enhance the development and commercialization prospects for TCB-002 and other products under CytoMed Therapeutics Limited (GDTC)?
**MWN-AI FAQ is based on asking OpenAI questions about TC BioPharm (Hol (OTC: TCBPY).
NASDAQ: TCBPY
TCBPY Trading
0.0% G/L:
$0.05 Last:
559 Volume:
$0.05 Open:
